Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

As the U.S. stock market navigates a period of uncertainty marked by unchanged interest rates and looming big-tech earnings, investors are keenly observing potential opportunities in various sectors.

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Merck , known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

(NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial hypertension ...

Men with PAH had a larger right heart size and worse survival than women, independent of body size and functional status, a ...